Clinical Trial: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07147101) titled 'Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment' on Aug. 21.

Brief Summary: To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.

Study Start Date: Sept. 01

Study Type: OBSERVATIONAL

Condition: Advanced Hepatocellular Carcinoma (HCC)

Intervention: DRUG: Sintilimab

Sintilimab will be administered by IV, 200 mg every 3 weeks

DRUG: Bevacizumab Biosimilar

Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 week...